Table 2.
Previous medications for CIU/CSU for ASTERIA I, ASTERIA II and GLACIAL (pooled) for the subgroup of patients with baseline angioedema and the subgroup of patients without baseline angioedema (all patients who received at least one dose of study drug)
| Patients with baseline angioedema N = 460 | Patients without baseline angioedema N = 515 | |
|---|---|---|
| Any medication use | 460 (100.0) | 515 (100.0) |
| Number previous CIU/CSU medications, mean (SD) | 5.4 (2.9) | 4.7 (2.7) |
| Antihistamines, n (%) | 460 (100.0) | 514 (99.8) |
| H2‐receptor antagonist, n (%) | 242 (52.6) | 230 (44.7) |
| Steroids, n (%) | 220 (47.8) | 226 (43.9) |
| Leukotriene‐receptor antagonist, n (%) | 182 (39.6) | 154 (29.9) |
| Immunosuppressants, n (%) | 51 (11.1) | 36 (7.0) |
| Other, n (%) | 240 (52.2) | 248 (48.2) |
Pooled data from the placebo and omalizumab groups. Previous medications for CIU/CSU presented in descending order for patients with baseline angioedema. Multiple uses of a specific medication per patient were counted once in the frequency for the medication. Similarly, multiple uses within a specific medication class per patient were counted once in the frequency for the medication class. Includes concomitant medications started at any time before first treatment date.
CIU/CSU, chronic idiopathic/spontaneous urticaria.